Baxter Healthcare (BAX): Long-Term Debt to Capital Ratio

Corporate emblem and logo of Baxter International (BAX)

Baxter International (BAX) CEO Jose Almeida is reorganizing the asset structure by spinning off the nephrology segment to optimize debt. Baxter International (BAX) leverages its status as a global leader in hospital system supplies, creating significant barriers to entry for new industry players. Market price action on GURU.Markets, where the indicator stands at 1.23, confirms steady demand for dialysis consumables, while restructuring costs are already priced into the securities.

Baxter Corp (BAX): Long-Term Debt to Capital from 07/04/2022 to 10/28/2026

Analytical breakdowns for Baxter International

- price and consensus price forecast:
Market Price Baxter International Inc.|BAX - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Baxter International|BAX - Enterprise Value
- book capitalization data:
Net Assets per Share Baxter|BAX - Book Capitalization|Market Cap to Net Assets Ratio baxter.com|BAX - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Baxter International|BAX - Long-Term Debt to Equity|Short-Term Debt to Equity baxter.com|BAX - Company Total Debt|Debt to Net Assets Ratio Baxter International|BAX - Company Long-Term Debts|Short-Term Debt Volume Baxter
Initial company analysis:BAX, Baxter International Inc.
Brand item of baxter.com

The scalable ecosystem of Baxter International (BAX), based on the supply of consumables for medical equipment, requires stable funding to maintain operational leverage. By analyzing the long-term debt-to-equity ratio, an investor assesses the proportion of loans with maturities exceeding one year relative to equity, which allows for the distinction between organic growth and hazardous borrowing. The trend for this metric reveals hidden asset freeze risks and confirms the resilience of the company's financial strategy.

Direct competitors

Long-Term Liabilities to Capital Intuitive Surgical, Inc.|Long-Term Debt to Capital Danaher Corp DHR|Long-Term Debt to Capital Ratio Becton Dickinson & Company (BDX)|Long-Term Debt to Capital STE|Ratio of Long-Term Indebtedness to Capital westpharma.com WST|MASI: Long-Term Debt to Capital|STVN - Long-Term Debt to Equity Ratio|TFX: Long-Term Debt to Capital|MMSI (Merit Medical Corp) - Long-Term Debt to Capital|Long-Term Debt to Equity Envista Holdings|Long-Term Debt to Equity icumed.com (ICUI)|Dentsply Sirona (XRAY) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient LeMaitre Vascular Inc (LMAT)|Long-Term Debt to Capital ATRC|STAAR Surgical Co - Ratio of Long-Term Indebtedness to Capital|ChromaDex Corp. (NAGE) - Long-Term Debt to Equity|ZIMV: Long-Term Debt to Capital Ratio|AngioDynamics - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Cerus Corp.|Alpha Teknova Inc (TKNO) - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio MGRM|Sharps Technology, Inc. (STSS) - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient infusystem.com INFU|Long-Term Debt to Equity Ratio UTMD (Utah Medical Products, Inc.)|KORU Medical Systems, Inc. - Long-Term Debt to Capital|NYXH: Long-Term Debt to Equity|MBOT - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital PDEX|ZTEK (zentek.com) - Long-Term Liabilities to Capital|Long-Term Debt to Equity Elutia (ELUT)|Long-Term Debt to Capital Ratio Milestone Scientific Inc (MLSS)|Long-Term Debt to Equity Ratio NEXGEL, Inc|Long-Term Loans to Capital Ratio RVP (retractable.com)|Long-Term Debt to Equity HBIO|Ratio of Long-Term Indebtedness to Capital femasys.com FEMY|MHUA - Long-Term Debt to Capital|POAI - Long-Term Debt to Equity|CJMB: Long-Term Debt to Capital|Long-Term Debt to Capital Atrion Corporation Inc.|Long-Term Debt to Equity Ratio NeuroMetrix, Inc. (NURO)